Annexon (ANNX) vs Olema Oncology (OLMA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Annexon (ANNX) has outperformed Olema Oncology (OLMA) over the past year, losing 27.4% versus a loss of 69.7%. Over five years, OLMA leads with a -66.4% price change compared with -77.4% for ANNX. Olema Oncology is the larger company by market cap ($615.0 million vs $591.4 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ANNX | OLMA |
|---|---|---|
| Share price | $3.10 | $7.02 |
| Market cap | $591.37M | $615.00M |
| 1-day change | -9.09% | -1.82% |
| YTD return | -38.25% | -71.92% |
| 1-year return | -27.40% | -69.70% |
| 5-year return | -77.37% | -66.36% |
| EPS (TTM) | $-1.01 | $-2.40 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-206.69M | $-162.45M |
| 52-week high | $7.18 | $36.26 |
| 52-week low | $3.07 | $6.24 |
| Distance from 52-week high | -56.82% | -80.64% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +448.39% | +405.70% |
| Average volume | 3.36M | 1.27M |
| Shares outstanding | 190.76M | 87.61M |
| Employees | 97 | 131 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ANNX has outperformed OLMA by 42.3 percentage points over the past year.
About Annexon
ANNX stock →Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. The company provides Tanruprubart, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase 2a clinical trial for the treatment of amyotrophic lateral sclerosis.
Health Care · Biotechnology: Pharmaceutical Preparations · 97 employees
About Olema Oncology
OLMA stock →Olema Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for breast cancers. The company's lead product candidate is palazestrant, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic ER-positive, human epidermal growth factor receptor 2-negative breast cancer; OPERA-01, the pivotal Phase 3 clinical trial of palazestrant as a monotherapy in second/third-line ER+/HER2- metastatic breast cancer; and palazestrant with CDK4/6 inhibitors, a phosphatidylinositol 3 kinase alpha (PI3Ka) inhibitor alpelisib, a mechanistic target of rapamycin inhibitor, and a CDK4 inhibitor that is in Phase 1b/2 clinical trial for the treatment of ER+/HER2- advanced or metastatic breast cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 131 employees
ANNX vs OLMA FAQ
Which is bigger, Annexon or Olema Oncology?
Olema Oncology (OLMA) is larger, with a market capitalization of $615.00M compared with $591.37M for Annexon (ANNX).
Which stock has performed better over the past year, ANNX or OLMA?
ANNX returned -27.40% over the past 12 months, compared with -69.70% for OLMA (price return, excluding dividends). Past performance does not predict future results.
Are Annexon and Olema Oncology in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.